NIH Research Matters
June 24, 2013
Brain Scan May Predict Best Depression Treatment
A brain imaging technique may help predict whether people with major depression will respond best to treatment with psychotherapy or a commonly prescribed drug. The approach might eventually be used as a tool to identify treatments that are most likely to succeed.
People with major depressive disorder, or major depression, have feelings of sadness, loss, anger or frustration that interfere with daily life for weeks or longer. Symptoms can also include memory loss and trouble focusing.
Major depression is most commonly treated with medication, psychotherapy or a combination. Unfortunately, less than 40% of patients typically respond well to initial treatment. They may need to try several treatments over many weeks or months before finally getting symptom relief.
A team led by Callie L. McGrath and Dr. Helen S. Mayberg at Emory University looked for a biological marker or “biomarker” that could predict whether patients with depression would respond best to medication or psychotherapy. The study was funded by NIH’s National Institute of Mental Health (NIMH) and National Institute of General Medical Sciences (NIGMS). Results appeared online on June 12, 2013, in JAMA Psychiatry.
The researchers studied 63 adults, ages 18 to 60, with major depression. Participants underwent a brain scan using positron emission tomography (PET). A small amount of radioactively labeled glucose was used to reveal levels of glucose metabolism—a sign of brain activity—in different areas of the brain. Participants then completed 12 weeks of treatment with cognitive behavior therapy or the drug escitalopram.
Success rates were similar for both treatments: about 36% for psychotherapy and 40% for escitalopram. The rates of those who didn’t respond were also similar: about 27% for psychotherapy and 20% for escitalopram.
Activity in a number of brain regions corresponded to treatment outcomes. The strongest correlation was in an area known as the anterior insula. Increased glucose metabolism in this area corresponded to successful treatment with medication but poor response to behavior therapy. Conversely, decreased glucose metabolism in the area was associated with success using behavior therapy but not escitalopram. One limitation of this potential imaging biomarker, the researchers note, is that it may not predict when neither of these therapies would work.
“Our goal is to develop reliable biomarkers that match an individual patient to the treatment option most likely to be successful, while also avoiding those that will be ineffective,” says Mayberg. “If these findings are confirmed in follow-up replication studies, scans of anterior insula activity could become clinically useful to guide more effective initial treatment decisions, offering a first step towards personalized medicine measures in the treatment of major depression.”
- Predicting Treatment Response to a Rapid Antidepressant:
- Genetic Switch Involved in Depression:
- Medication Quickly Lifts Bipolar Depression Symptoms:
- Depression (Age Page):
Reference: JAMA Psychiatry. 2013 Jun 12:1-9. doi: 10.1001/jamapsychiatry.2013.143. [Epub ahead of print]. PMID: 23760393.
Funding: NIH’s National Institute of Mental Health (NIMH) and National Institute of General Medical Sciences (NIGMS).
NIH Research Matters
Bldg. 31, Rm. 5B64A, MSC 2094
Bethesda, MD 20892-2094
About NIH Research Matters
Editor: Harrison Wein, Ph.D.
Assistant Editors: Vicki Contie, Carol Torgan, Ph.D.
NIH Research Matters is a weekly update of NIH research highlights from the Office of Communications and Public Liaison, Office of the Director, National Institutes of Health.